rosiglitazone has been researched along with deoxycytidine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T | 1 |
Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM | 1 |
3 other study(ies) available for rosiglitazone and deoxycytidine
Article | Year |
---|---|
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
PPARĪ³ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2013 |